Targeting heat shock proteins in prostate cancer

Current Medicinal Chemistry

Volumn 20, Issue 22, 2013, Pages 2731-2740

  Hessenkemper, W ^a   Baniahmad, A ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Androgen receptor; Chaperones; Heat shock proteins; Prostate cancer therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CUSTIRSEN; GENISTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; KU 174; MJC 13; OGX 427; PF 04928473; PROTOLICHESTERINIC ACID; RADICICOL; RETASPIMYCIN; TANESPIMYCIN; UNCLASSIFIED DRUG; VICANICIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL METABOLISM; CELL PROTECTION; CELL SURVIVAL; DRUG MECHANISM; HUMAN; MITOGENESIS; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; HEAT-SHOCK PROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84880303350     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320220001     Document Type: Article

References (113)

1. Young, J.C.; Agashe, V.R.; Siegers, K.; Hartl, F.U. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol., 2004, 5, 781-791.
2. Garrido, C.; Brunet, M.; Didelot, C.; Zermati, Y.; Schmitt, E.; Kroemer, G. Heat shock proteins 27 and 70: Anti-apoptotic proteins with tumorigenic properties. Cell Cycle, 2006, 5, 2592-2601.
3. Parcellier, A.; Gurbuxani, S.; Schmitt, E.; Solary, E.; Garrido, C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem. Biophys. Res. Commun., 2003, 304, 505-512.
4. Hut, H.M.; Kampinga, H.H.; Sibon, O.C. Hsp70 protects mitotic cells against heat-induced centrosome damage and division abnormalities. Mol. Biol. Cell, 2005, 16, 3776-3785.
5. Jego, G.; Hazoumé, A.; Seigneuric, R.; Garrido C. Targeting heat shock proteins in cancer. Cancer Lett., 2010, Nov 13.
6. Zoubeidi, A.; Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int. J. Biochem. Cell Biol., 2012, 44, 1646-1656.
7. Garrido, C. Size matters: Of the small HSP27 and its large oligomers. Cell Death Differ., 2002, 9, 483-485.
8. Voss, O.H.; Batra, S.; Kolattukudy, S.J.; Gonzalez-Mejia, M.E.; Smith, J.B.; Doseff, A.I. Binding of caspase-3 prodomain to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. J. Biol. Chem., 2007, 282, 25088-25099.
9. Lindner, R.A.; Carver, J.A.; Ehrnsperger, M.; Buchner, J.; Esposito, G.; Behlke, J.; Lutsch, G.; Kotlyarov, A.; Gaestel, M. Mouse Hsp25, a small shock protein. The role of its C-terminal extension in oligomerization and chaperone action. Eur. J. Biochem., 2000, 267, 1923-1932.
10. Jaya, N.; Garcia, V.; Vierling, E. Substrate binding site flexibility of the small heat shock protein molecular chaperones. Proc. Natl. Acad. Sci. U S A., 2009, 106, 15604-15609.
11. Zoubeidi, A.; Zardan, A.; Beraldi, E.; Fazli, L.; Sowery, R.; Rennie, P.; Nelson, C.; Gleave, M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res., 2007, 67, 10455-10465.
12. Rogalla, T.; Ehrnsperger, M.; Preville, X.; Kotlyarov, A.; Lutsch, G.; Ducasse, C.; Paul, C.; Wieske, M.; Arrigo, A.P.; Buchner, J.; Gaestel M. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J. Biol. Chem., 1999, 274, 18947-18956.
13. Kostenko, S.; Moens, U. Heat shock protein 27 phosphorylation: Kinases, phosphatases, functions and pathology. Cell Mol. Life Sci., 2009, 66, 3289-3307.
14. Garrido, C.; Paul, C.; Seigneuric, R.; Kampinga, H.H. The small heat shock proteins family: The long forgotten chaperones. Int. J. Biochem. Cell Biol., 2012, 44, 1588-1592.
15. Schneider, G.B.; Hamano, H.; Cooper, L.F. In vivo evaluation of hsp27 as an inhibitor of actin polymerization: Hsp27 limits actin stress fiber and focal adhesion formation after heat shock. J. Cell Physiol., 1998, 177, 575-584.
16. Concannon, C.G.; Orrenius, S.; Samali, A. Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both procaspase-3 and cytochrome c. Gene Expr., 2001, 9, 195-201.
17. Bruey, J.M.; Paul, C.; Fromentin, A.; Hilpert, S.; Arrigo, A.P.; Solary, E.; Garrido, C. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene., 2000, 19, 4855-4863.
18. Shi, Y.; Thomas, J.O. The transport of proteins into the nucleus requires the 70-kilodalton heat shock protein or its cytosolic cognate. Mol. Cell Biol., 1992, 12, 2186-2192.
19. Tavaria, M.; Gabriele, T.; Kola, I.; Anderson, R.L. A hitchhiker's guide to the human Hsp70 family. Cell Stress Chaperones, 1996, 1, 23-28.
20. Stebbins, C.E.; Russo, A.A.; Schneider, C.; Rosen, N.; Hartl, F.U.; Pavletich, N.P. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell, 1997, 89, 239-250.
21. Onuoha, S.C.; Coulstock, E.T.; Grossmann, J.G.; Jackson, S.E. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J. Mol. Biol., 2008, 379, 732-744.
22. Nathan, D.F.; Lindquist, S. Mutational analysis of Hsp90 function: Interactions with a steroid receptor and a protein kinase. Mol. Cell Biol., 1995, 15, 3917-3925.
23. Sato, S.; Fujita, N.; Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA., 2000, 97, 10832-10837.
24. Kovacs, J.J.; Murphy, P.J.; Gaillard, S.; Zhao, X.; Wu, J.T.; Nicchitta, C.V.; Yoshida, M.; Toft, D.O.; Pratt, W.B.; Yao, T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell, 2005, 18, 601-607.
25. Duval, M.; Le Boeuf, F.; Huot, J.; Gratton, J.P. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell., 2007, 18, 4659-4668.
26. Mjahed, H.; Girodon, F.; Fontenay, M.; Garrido, C. Heat shock proteins in hematopoietic malignancies. Exp. Cell Res., 2012, 318, 1946-1958.
27. Didelot, C.; Lanneau, D.; Brunet, M.; Joly, A.L.; De Thonel, A.; Chiosis, G.; Garrido, C. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr. Med. Chem., 2007, 14, 2839-2847.
28. Wang, R.E. Targeting heat shock proteins 70/90 and proteasome for cancer therapy. Curr. Med. Chem., 2011, 18, 4250-4264.
29. Pratt, W.B.; Toft, D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood)., 2003, 228, 111-133.
30. Beere, H.M. "The stress of dying": The role of heat shock proteins in the regulation of apoptosis. J. Cell Sci., 2004, 117, 2641-2651.
31. Calderwood, S.K.; Khaleque, M.A.; Sawyer, D.B.; Ciocca, D.R. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem. Sci., 2006, 31, 164-172.
32. Agoff, S.N.; Hou, J.; Linzer, D.I.; Wu, B. Regulation of the human hsp70 promoter by p53. Science, 1993, 259, 84-87.
33. Tsutsumi-Ishii, Y.; Tadokoro, K.; Hanaoka, F.; Tsuchida, N. Response of heat shock element within the human HSP70 promoter to mutated p53 genes. Cell Growth Differ., 1995, 6, 1-8.
34. Madden, S.L.; Galella, E.A.; Zhu, J.; Bertelsen, A.H.; Beaudry, G.A. SAGE transcript profiles for p53-dependent growth regulation. Oncogene, 1997, 15, 1079-1085.
35. Khaleque, M.A.; Bharti, A.; Sawyer, D.; Gong, J.; Benjamin, I.J.; Stevenson, M.A.; Calderwood, S.K. Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth. Oncogene, 2005, 24, 6564-6573.
36. Wu, C. Heat shock transcription factors: Structure and regulation. Annu. Rev. Cell Dev. Biol., 1995, 11, 441-469.
37. Hoang, A.T.; Huang, J.; Rudra-Ganguly, N.; Zheng, J.; Powell, W.C.; Rabindran, S.K.; Wu, C.; Roy-Burman, P. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am. J. Pathol., 2000, 156, 857-864.
38. Bader, A.G.; Kang, S.; Zhao, L.; Vogt, P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer, 2005, 5, 921-929.
39. Taira, T.; Sawai, M.; Ikeda, M.; Tamai, K.; Iguchi-Ariga, S.M.; Ariga, H. Cell cycle-dependent switch of up-and down-regulation of human hsp70 gene expression by interaction between c-Myc and CBF/NF-Y. J. Biol. Chem., 1999, 274, 24270-24279.
40. Teng, S.C.; Chen, Y.Y.; Su, Y.N.; Chou, P.C.; Chiang, Y.C.; Tseng, S.F.; Wu, K.J. Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation. J. Biol. Chem., 2004, 279, 14649-14655.
41. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M.F.; Fritz, L.C.; Burrows, F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 2003, 425, 407-410.
42. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med., 2002, 8, 55-61.
43. Pratt, W.B.; Galigniana, M.D.; Harrell, J.M.; DeFranco, D.B. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal., 2004, 16, 857-872.
44. Ciocca, D.R.; Calderwood, S.K. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones, 2005, 10, 86-103.
45. Nimmanapalli, R.; O'Bryan, E.; Bhalla, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Ablpositive human leukemic blasts. Cancer Res., 2001, 61, 1799-1804.
46. Pick, E.; Kluger, Y.; Giltnane, J.M.; Moeder, C.; Camp, R.L.; Rimm, D.L.; Kluger, H.M. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res., 2007, 67, 2932-2937.
47. Shimamura, T.; Shapiro, G.I. Heat shock protein 90 inhibition in lung cancer. J. Thorac. Oncol., 2008, 3, 152-159.
48. Nylandsted, J.; Brand, K.; Jäättelä M. Heat shock protein 70 is required for the survival of cancer cells. Ann. N. Y. Acad. Sci., 2000, 926, 122-125.
49. Gurbuxani, S.; Schmitt, E.; Cande, C.; Parcellier, A.; Hammann, A.; Daugas, E.; Kouranti, I.; Spahr, C.; Pance, A.; Kroemer, G.; Garrido, C. Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene, 2003, 22, 6669-6678.
50. Whelan, R.D.; Hill, B.T. Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation. Breast Cancer Res. Treat., 1993, 26, 23-39.
51. Richards, E.H.; Hickey, E.; Weber, L.; Master, J.R. Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res., 1996, 56, 2446-2451.
52. Jäättelä, M. Escaping cell death: Survival proteins in cancer. Exp. Cell Res., 1999, 248, 30-43.
53. Tatar, M.; Khazaeli, A.A.; Curtsinger, J.W. Chaperoning extended life. Nature, 1997, 390, 30.
54. Hsu, A.L.; Murphy, C.T.; Kenyon, C. Regulation of aging and agerelated disease by DAF-16 and heat-shock factor. Science, 2003, 300, 1142-1145.
55. Workman, P. Altered states: Selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med., 2004, 10, 47-51.
56. Heinlein, C.A.; Chang, C. Role of chaperones in nuclear translocation and transactivation of steroid receptors. Endocrine., 2001, 14, 143-149.
57. Tenbaum, S.; Baniahmad, A. Nuclear receptors: Structure, function and involvement in disease. Int. J. Biochem. Cell Biol., 1997, 29, 1325-1341.
58. Brinkmann, A.O.; Trapman, J. Prostate cancer schemes for androgen escape. Nat. Med., 2000, 6, 628-629.
59. Dehm, S.M.; Tindall, D.J. Androgen receptor structural and functional elements: Role and regulation in prostate cancer. Mol. Endocrinol., 2007, 21, 2855-2863.
60. Edwards, B.K.; Ward, E.; Kohler, B.A.; Eheman, C.; Zauber, A.G.; Anderson, R.N.; Jemal, A.; Schymura, M.J.; Lansdorp-Vogelaar, I.; Seeff, L.C.; van Ballegooijen, M.; Goede, S.L.; Ries, L.A. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer., 2010, 116, 544-573.
61. Feldman, B.J.; Feldman, D. The development of androgenindependent prostate cancer. Nat. Rev. Cancer, 2001, 1, 34-45.
62. Georget, V.; Térouanne, B.; Nicolas, J.C.; Sultan, C. Mechanism of antiandrogen action: Key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry, 2002, 41, 11824-11831.
63. Saporita, A.J.; Ai, J.; Wang, Z. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate, 2007, 67, 509-520.
64. Basak, S.; Pookot, D.; Noonan, E.J.; Dahiya, R. Genistein downregulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol. Cancer Ther., 2008, 7, 3195-3202.
65. Murphy, P.J.; Morishima, Y.; Kovacs, J.J.; Yao, T.P.; Pratt, W.B. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem., 2005, 280, 33792-33799.
66. Suzuki, Y.; Kondo, Y.; Hara, S.; Kimata, R.; Nishimura, T. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions. Int. J. Urol., 2010, 17, 281-285.
67. Foster, C.S.; Dodson, A.R.; Ambroisine, L.; Fisher, G.; Møller, H.; Clark, J.; Attard, G.; De-Bono, J.; Scardino, P.; Reuter, V.E.; Cooper, C.S.; Berney, D.M.; Cuzick, J. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br. J. Cancer., 2009, 101, 1137-1144.
68. Rocchi, P.; Beraldi, E.; Ettinger, S.; Fazli, L.; Vessella, R.L.; Nelson, C.; Gleave, M. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res., 2005, 65, 11083-11093.
69. Cornford, P.A.; Dodson, A.R.; Parsons, K.F.; Desmond, A.D.; Woolfenden, A.; Fordham, M.; Neoptolemos, J.P.; Ke, Y.; Foster, C.S. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res., 2000, 60, 7099-7105.
70. Rocchi, P.; So, A.; Kojima, S.; Signaevsky, M.; Beraldi, E.; Fazli, L.; Hurtado-Coll, A.; Yamanaka, K.; Gleave, M. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res., 2004, 64, 6595-6602.
71. Zoubeidi, A.; Zardan, A.; Wiedmann, R.M.; Locke, J.; Beraldi, E.; Fazli, L.; Gleave, M.E. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res., 2010, 70, 2307-2317.
72. Andrieu, C.; Taieb, D.; Baylot, V.; Ettinger, S.; Soubeyran, P.; De-Thonel, A.; Nelson, C.; Garrido, C.; So, A.; Fazli, L.; Bladou, F.; Gleave, M.; Iovanna, J.L.; Rocchi, P. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene, 2010, 29, 1883-1896.
73. Xu, L.; Chen, S.; Bergan, R.C. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene, 2006, 25, 2987-2998.
74. Di, K.; Wong, Y.C.; Wang, X. Id-1 promotes TGF-beta1-induced cell motility through HSP27 activation and disassembly of adherens junction in prostate epithelial cells. Exp. Cell Res., 2007, 313, 3983-3999.
75. Tang, D.; Khaleque, M.A.; Jones, E.L.; Theriault, J.R.; Li, C.; Wong, W.H.; Stevenson, M.A.; Calderwood, S.K. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones, 2005, 10, 46-58.
76. Lu, S.; Tan, Z.; Wortman, M.; Lu, S.; Dong, Z. Regulation of heat shock protein 70-1 expression by androgen receptor and its signaling in human prostate cancer cells. Int. J. Oncol., 2010, 36, 459-467.
77. Periyasamy, S.; Hinds, T. Jr.; Shemshedini, L.; Shou, W.; Sanchez, E.R. FKBP51 and Cyp40 are positive regulators of androgendependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene, 2010, 29, 1691-701.
78. Paulson, H.L.; Fischbeck, K.H. Trinucleotide repeats in neurogenetic disorders. Annu. Rev. Neurosci., 1996, 19, 79-107.
79. Stenoien, D.L.; Cummings, C.J.; Adams, H.P.; Mancini, M.G.; Patel, K.; DeMartino, G.N.; Marcelli, M.; Weigel, N.L.; Mancini, M.A. Polyglutamine- expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet., 1999, 8, 731-741.
80. Kobayashi, Y.; Kume, A.; Li, M.; Doyu, M.; Hata, M.; Ohtsuka, K.; Sobue, G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem., 2000, 275, 8772-8778.
81. Rutherford, S.L.; Lindquist, S. Hsp90 as a capacitor for morphological evolution. Nature, 1998, 396, 336-342.
82. Banerji, U.; Walton, M.; Raynaud, F.; Grimshaw, R.; Kelland, L.; Valenti, M.; Judson, I.; Workman, P. Pharmacokinetic-pharmaco dynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin. Cancer Res., 2005, 11, 7023-7032.
83. Eiseman, J.L.; Lan, J.; Lagattuta, T.F.; Hamburger, D.R.; Joseph, E.; Covey, J.M.; Egorin, M.J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino] geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol., 2005, 55, 21-32.
84. Pacey, S.; Banerji, U.; Judson, I.; Workman, P. Hsp90 inhibitors in the clinic. Handb. Exp. Pharmacol., 2006, 172, 331-358.
85. Johnson, J.L.; Toft, D.O. Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol. Endocrinol., 1995, 9, 670-678.
86. Rao, R.; Fiskus, W.; Yang, Y.; Lee, P.; Joshi, R.; Fernandez, P.; Mandawat, A.; Atadja, P.; Bradner, J.E.; Bhalla K. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood, 2008, 112, 1886-1893.
87. Plescia, J.; Salz, W.; Xia, F.; Pennati, M.; Zaffaroni, N.; Daidone, M.G.; Meli, M.; Dohi, T.; Fortugno, P.; Nefedova, Y.; Gabrilovich, D.I.; Colombo, G.; Altieri, D.C. Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 2005, 7, 457-468.
88. Schmitt, E.; Parcellier, A.; Gurbuxani, S.; Cande, C.; Hammann, A.; Morales, M.C.; Hunt, C.R.; Dix, D.J.; Kroemer, R.T.; Giordanetto, F.; Jäättelä, M.; Penninger, J.M.; Pance, A.; Kroemer, G.; Garrido, C. Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. Cancer Res., 2003, 63, 8233-8240.
89. Ray, S.; Lu, Y.; Kaufmann, S.H.; Gustafson, W.C.; Karp, J.E.; Boldogh, I.; Fields, A.P.; Brasier, A.R. Genomic mechanisms of p210BCR-ABL signaling: Induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J. Biol. Chem., 2004, 279, 35604-35615.
90. Leu, J.I.; Pimkina, J.; Frank, A.; Murphy, M.E.; George, D.L. A small molecule inhibitor of inducible heat shock protein 70. Mol. Cell., 2009, 36, 15-27.
91. Song, T.F.; Zhang, Z.F.; Liu, L.; Yang, T.; Jiang, J.; Li, P. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910). J. Int. Med. Res., 2009, 37, 1375-1388.
92. Arceci, R.J. Mechanisms of resistance to therapy and tumor cell survival. Curr. Opin. Hematol., 1995, 2, 268-274.
93. Denmeade, S.R.; Lin, X.S.; Isaacs, J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 1996, 28, 251-265.
94. Giménez Ortiz, A.; Montalar Salcedo, J. Heat shock proteins as targets in oncology. Clin. Transl. Oncol., 2010, 12, 166-173.
95. O'Malley, K.J.; Langmann, G.; Ai, J.; Ramos-Garcia, R.; Vessella, R.L.; Wang, Z. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate, 2012, 72, 1117-1123.
96. Solit, D.B.; Zheng, F.F.; Drobnjak, M.; Münster, P.N.; Higgins, B.; Verbel, D.; Heller, G.; Tong, W.; Cordon-Cardo, C.; Agus, D.B.; Scher, H.I.; Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res., 2002, 8, 986-993.
97. Yano, A.; Tsutsumi, S.; Soga, S.; Lee, M.J.; Trepel, J.; Osada, H.; Neckers, L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc. Natl. Acad. Sci. USA., 2008, 105, 15541-15546.
98. Lamoureux, F.; Thomas, C.; Yin, M.J.; Kuruma, H.; Fazli, L.; Gleave, M.E.; Zoubeidi, A. A novel HSP90 inhibitor delays castrateresistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin. Cancer Res., 2011, 17, 2301-2313.
99. Zhang, Y.; Kwon, S.; Yamaguchi, T.; Cubizolles, F.; Rousseaux, S.; Kneissel, M.; Cao, C.; Li, N.; Cheng, H.L.; Chua, K.; Lombard, D.; Mizeracki, A.; Matthias, G.; Alt, F.W.; Khochbin, S.; Matthias, P. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell Biol., 2008, 28, 1688-1701.
100. Ai, J.; Wang, Y.; Dar, J.A.; Liu, J.; Liu, L.; Nelson, J.B.; Wang, Z. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castrationresistant prostate cancer. Mol. Endocrinol., 2009, 23, 1963-1972.
101. Eskew, J.D.; Sadikot, T.; Morales, P.; Duren, A.; Dunwiddie, I.; Swink, M.; Zhang, X.; Hembruff, S.; Donnelly, A.; Rajewski, R.A.; Blagg, B.S.; Manjarrez, J.R.; Matts, R.L.; Holzbeierlein, J.M.; Vielhauer, G.A. Development and characterization of a novel Cterminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer., 2011, 31, 468.
102. Lamoureux, F.; Thomas, C.; Yin, M.J.; Kuruma, H.; Beraldi, E.; Fazli, L.; Zoubeidi, A.; Gleave, M.E. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res., 2011, 71, 5838-5849.
103. Oh, W.K.; Galsky, M.D.; Stadler, W.M.; Srinivas, S.; Chu, F.; Bubley, G.; Goddard, J.; Dunbar, J.; Ross, R.W. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology, 2011, 78, 626-630.
104. Harashima, K.; Akimoto, T.; Nonaka, T.; Tsuzuki, K.; Mitsuhashi, N.; Nakano, T. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor. Int. J. Radiat. Biol., 2005, 81, 63-76.
105. Migliaccio, A.; Castoria, G.; Di Domenico, M.; de Falco, A.; Bilancio, A.; Lombardi, M.; Barone, M.V.; Ametrano, D.; Zannini, M.S.; Abbondanza, C.; Auricchio, F. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J., 2000, 16, 5406-5417.
106. Razandi, M.; Pedram, A.; Levin, E.R. Heat shock protein 27 is required for sex steroid receptor trafficking to and functioning at the plasma membrane. Mol. Cell. Biol., 2010, 30, 3249-3261.
107. Schwartz, G.G.; Hulka, B.S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res., 1990, 10, 1307-1311.
108. Barnes, S. Role of phytochemicals in prevention and treatment of prostate cancer. Epidemiol. Rev., 2001, 223, 102-105.
109. Russo, A.; Caggia, S.; Piovano, M.; Garbarino, J.; Cardile, V. Effect of vicanicin and protolichesterinic acid on human prostate cancer cells: Role of Hsp70 protein. Chem. Biol. Interact., 2012, 195, 1-10.
110. Liu, S.; Yuan, Y.; Okumura, Y.; Shinkai, N.; Yamauchi, H. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth. Biochem. Biophys. Res. Commun., 2010, 394, 297-302.
111. Magee, P.J.; Rowland, I.R. Phyto-oestrogens, their mechanism of action: Current evidence for a role in breast and prostate cancer. Br. J. Nutr., 2004, 91, 513-531.
112. De Leon, J.T.; Iwai, A.; Feau, C.; Garcia, Y.; Balsiger, H.A.; Storer, C.L.; Suro, R.M.; Garza, K.M; Lee, S.; Kim, Y.S.; Chen, Y.; Ning, Y.M.; Riggs, D.L.; Fletterick, R.J.; Guy, R.K.; Trepel, J.B.; Neckers, L.M.; Cox, M.B. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc. Natl. Acad. Sci. USA., 2011, 108, 11878-11883.
113. Riggs, D.L.; Roberts, P.J.; Chirillo, S.C.; Cheung-Flynn, J.; Prapapanich, V.; Ratajczak, T.; Gaber, R.; Picard, D.; Smith, D.F. The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J., 2003, 22, 1158-1167.